Nivolumab
- PDF / 169,164 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 56 Downloads / 148 Views
1 S
Various toxicities: 5 case reports A retrospective study of 118 histologically proven metastatic renal cell carcinoma (mRCC) patients, who received nivolumab in Japan between March 2013 and August 2019, described nine patients [ages and sexes not stated], who developed myasthenia gravis, anorexia, heart failure, renal failure or destructive thyroiditis during treatment with nivolumab for mRCC [routes, dosages, durations of treatments to reactions onsets not stated]. All patients received at least two cycles of nivolumab. The patient with destructive thyroiditis received unspecified corticosteroid therapy; however, there was no recovery. Therefore, this patient received thyroid hormone replacement [outcomes not stated]. Numakura K, et al. Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes. International Journal of Clinical 803508343 Oncology 25: 1543-1550, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1007/s10147-020-01693-y
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
